[go: up one dir, main page]

AR127521A2 - Composiciones y métodos para suministro a la barrera hematoencefálica - Google Patents

Composiciones y métodos para suministro a la barrera hematoencefálica

Info

Publication number
AR127521A2
AR127521A2 ARP220102974A ARP220102974A AR127521A2 AR 127521 A2 AR127521 A2 AR 127521A2 AR P220102974 A ARP220102974 A AR P220102974A AR P220102974 A ARP220102974 A AR P220102974A AR 127521 A2 AR127521 A2 AR 127521A2
Authority
AR
Argentina
Prior art keywords
blood
antigen
brain barrier
compositions
supply
Prior art date
Application number
ARP220102974A
Other languages
English (en)
Inventor
Suzanne Edavettal
Sanjaya Singh
Derrick Domingo
Deepti Wilkinson
Pilar Cejudo-Martin
Pharavee Jaisprasart
Brian Geist
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR127521A2 publication Critical patent/AR127521A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen anticuerpos monoclonales anti-TfR y fragmentos de unión al antígeno de estos para suministrar un agente al cerebro de un sujeto que lo necesita. Además, se describen conjugados y construcciones de fusión que contienen el anticuerpo anti-TfR o fragmento de unión al antígeno de este acoplado a un agente terapéutico o de diagnóstico, tal como un segundo anticuerpo y fragmento de unión al antígeno de este, para tratar o detectar un trastorno neurológico y/o suministrar un agente terapéutico o de diagnóstico a través de la barrera hematoencefálica. También se describen ácidos nucleicos que codifican los anticuerpos, conjugados y constructos de fusión y células huésped recombinantes relacionadas.
ARP220102974A 2020-04-08 2022-10-31 Composiciones y métodos para suministro a la barrera hematoencefálica AR127521A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063006998P 2020-04-08 2020-04-08
US202063036020P 2020-06-08 2020-06-08

Publications (1)

Publication Number Publication Date
AR127521A2 true AR127521A2 (es) 2024-01-31

Family

ID=78022500

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP220102974A AR127521A2 (es) 2020-04-08 2022-10-31 Composiciones y métodos para suministro a la barrera hematoencefálica
ARP220102973A AR127520A2 (es) 2020-04-08 2022-10-31 Composiciones y métodos para suministro a la barrera hematoencefálica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP220102973A AR127520A2 (es) 2020-04-08 2022-10-31 Composiciones y métodos para suministro a la barrera hematoencefálica

Country Status (13)

Country Link
US (2) US20230174646A1 (es)
EP (1) EP4132589A4 (es)
JP (1) JP2023520821A (es)
KR (1) KR20220164773A (es)
CN (1) CN116096427B (es)
AR (2) AR127521A2 (es)
AU (1) AU2021253820A1 (es)
BR (1) BR112022020275A2 (es)
CA (1) CA3179911A1 (es)
IL (1) IL297148A (es)
MX (1) MX2022012635A (es)
TW (1) TW202204413A (es)
WO (1) WO2021205358A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115697393A (zh) * 2020-04-08 2023-02-03 詹森生物科技公司 抗PHF-tau抗体及其用途
JP2025512732A (ja) 2022-03-11 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 多重特異性抗体及びその使用
IL315541A (en) 2022-03-11 2024-11-01 Janssen Pharmaceutica Nv Multispecific antibodies and their uses
KR20240156640A (ko) 2022-03-11 2024-10-30 얀센 파마슈티카 엔브이 다중특이적 항체 및 이의 용도
CN119421893A (zh) * 2022-03-31 2025-02-11 威斯塔解剖学和生物学研究所 针对人类Siglec-7的抗体及其用于免疫疗法的用途
CN119497720A (zh) * 2022-07-01 2025-02-21 戴纳立制药公司 将寡核苷酸递送至细胞的转铁蛋白受体结合分子缀合物
TW202405020A (zh) * 2022-07-29 2024-02-01 美商阿列克特有限責任公司 轉鐵蛋白受體抗原結合域及其用途
MA71684A (fr) * 2022-08-05 2025-05-30 Janssen Biotech, Inc. Protéines de liaison de récepteur de transferrine pour traitement de tumeurs cérébrales
WO2025024334A1 (en) 2023-07-21 2025-01-30 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025021790A2 (en) * 2023-07-24 2025-01-30 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2025172924A1 (en) 2024-02-15 2025-08-21 Janssen Biotech, Inc. Anti-transferrin receptor compositions and methods thereof
WO2025230358A1 (ko) * 2024-05-03 2025-11-06 한양대학교 산학협력단 엔도좀 탈출 효율이 향상된 항 인간 트랜스페린 수용체 항체, 및 이를 이용한 다중특이적 항체 및 약학 조성물
CN119192378B (zh) * 2024-10-16 2025-10-17 中国人民解放军军事科学院军事医学研究院 一种pH敏感型人源抗转铁蛋白受体1抗体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521907A (ja) * 2004-12-03 2008-06-26 シェーリング コーポレイション 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー
US20120171120A1 (en) * 2010-11-30 2012-07-05 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
JP2014514313A (ja) * 2011-04-20 2014-06-19 ロシュ グリクアート アクチェンゲゼルシャフト 血液脳関門のｐＨ依存性通過のための方法及び構築物
KR102031317B1 (ko) * 2012-05-21 2019-10-14 제넨테크, 인크. 혈액-뇌 장벽 수송의 안전성을 개선하는 방법
CA2890455A1 (en) * 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
IL242088B2 (en) * 2013-05-20 2023-12-01 Genentech Inc Anti-transferrin receptor antibodies and methods of use
RU2694659C2 (ru) * 2014-01-06 2019-07-16 Ф. Хоффманн-Ля Рош Аг Одновалентные модули-переносчики через гематоэнцефалический барьер
EP3221361B1 (en) * 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
JP6779876B2 (ja) * 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
IL255416B2 (en) * 2015-05-04 2024-06-01 Cytomx Therapeutics Inc Anti-CD71 antibodies, activatable anti-CD71 antibodies, preparations containing them and their uses
UA123053C2 (uk) * 2015-06-24 2021-02-10 Ф. Хоффманн-Ля Рош Аг Антитіло до рецептора трансферину зі спеціально підібраною афінністю
WO2018011353A1 (en) * 2016-07-14 2018-01-18 Bioarctic Ab Brain delivery protein
TWI780237B (zh) * 2017-10-14 2022-10-11 美商艾伯維公司 抗－ｃｄ７１可活化之抗體藥物共軛物及其使用方法
CA3080351A1 (en) * 2017-11-02 2019-05-09 Ossianix, Inc. Improved tfr-selective binding peptides capable of crossing the blood brain barrier
CN112203725A (zh) * 2018-06-13 2021-01-08 诺华股份有限公司 Bcma嵌合抗原受体及其用途
EP3853254A1 (en) * 2018-09-20 2021-07-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd123 immunotherapy

Also Published As

Publication number Publication date
CN116096427A (zh) 2023-05-09
CA3179911A1 (en) 2021-10-14
KR20220164773A (ko) 2022-12-13
AU2021253820A1 (en) 2022-11-24
IL297148A (en) 2022-12-01
US20260008846A1 (en) 2026-01-08
EP4132589A1 (en) 2023-02-15
AR127520A2 (es) 2024-01-31
BR112022020275A2 (pt) 2022-12-27
US20230174646A1 (en) 2023-06-08
MX2022012635A (es) 2023-01-11
WO2021205358A1 (en) 2021-10-14
TW202204413A (zh) 2022-02-01
JP2023520821A (ja) 2023-05-19
EP4132589A4 (en) 2024-05-08
CN116096427B (zh) 2025-11-28

Similar Documents

Publication Publication Date Title
AR127521A2 (es) Composiciones y métodos para suministro a la barrera hematoencefálica
AR127519A2 (es) Anticuerpos anti-cd98 y usos de estos
BR112015010046A2 (pt) Proteínas de ligação a antígeno ou um fragmento de ligação a antígeno da mesma e seu método de produção, vetor, célula hospedeira de microrganismo transgênico, imunoconjugado e seu uso, composição farmacêutica e hibridoma murino
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
CO6351751A2 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CO2020000357A2 (es) Receptores de células t novedosos, e inmunoterapia usando los mismos
MX2022005916A (es) Virus adenoasociado terapeutico que comprende promotores especificos del higado para el tratamiento de la enfermedad de pompe y los trastornos liposomales.
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
FI3736291T3 (fi) Anti-fcrh5-vasta-aineita
Muthumani et al. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody
MX2023003039A (es) Agentes y metodos para el suministro dirigido a celulas.
MX2024010983A (es) Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control.
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
BR112021017046A2 (pt) Receptores de antígeno quiméricos antirreceptores de folato 1 humanizados e seus usos
PE20230682A1 (es) Anticuerpo anti-ox40 y usos del mismo
BR112022009482A2 (pt) Anticorpo monoclonal anti-b7-h3 e métodos de uso do mesmo
CL2021003335A1 (es) Anticuerpo biespecífico para a-syn/igf1r y uso de este.
CL2025002218A1 (es) Células que expresan un car anti-mesotelina
AR121803A1 (es) Composiciones y métodos para suministro a la barrera hematoencefálica
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.
AR121802A1 (es) Anticuerpos anti-cd98 y usos de estos
BR112023025810A2 (pt) Agentes e métodos para ativação e direcionamento de células imunes efetoras
MX2024011081A (es) Anticuerpos multiespecíficos y usos de estos.
MX2023013611A (es) Fusiones de anticuerpo-protamina como compuestos de direccionamiento de una nanoparticula basada en protamina.
US11952410B2 (en) Mesothelin-targeted trail trimer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal